Clinical experience with posaconazole in patients with invasive mucormycosis: a case series.
Posaconazole (POS) is approved for prophylaxis of Aspergillus and Candida infections in immunocompromised patients and for the treatment of oropharyngeal candidiasis. Data is limited as step-down therapy after treatment with amphotericin B (AMB). Four cases with refractory mucormycosis who had a favorable response after a change in antifungal therapy to POS are presented. In these four patients, POS demonstrated to be an effective therapeutic option in the management of refractory mucormycosis. Further studies should be conducted to define its role, whether as a single agent or as adjuvant therapy in combination with AMB.
González-Ramos
Michelle M
MM
Department of Internal Medicine, Infectious Diseases Section, University of Puerto Rico School of Medicine, PO Box 365067, San Juan, PR. mgonzalezmd@yahoo.com
Bertrán-Pasarell
Jorge
J
Guiot
Humberto
H
Soto
Ruth
R
Santana
Jorge
J
Amador
Rosana
R
Conde
Ana
A
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy*; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole